Physicians' Academy for Cardiovascular Education

How do we figure out the “optimal dose” of a NOAC for our patients?

Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

When do we dose differently from the recommendations in the “package insert”? Why do we often “underdose” NOACs?

Lecture - Aug. 28, 2016 - Rome, Italy - Samuel Z Goldhaber, MD – Boston, MA, USA

As part of a shared session at the Brigham and Women's Hospital and PACE-cme Transatlantic Dialogue, Samuel Z Goldhaber considered the balance between the effect of NOACs on efficacy in preventing stroke and the risk of bleeding. How can NOACs best be dosed for an optimal balance?

Educational information

Brigham and Women’s Transatlantic Dialogues on Controversies in Contemporary Cardiology

This lecture is part of a special educational symposium exploring controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic. American and European experts discussed novel insights from basic and translational cardiovascular science in the context of ongoing and future clinical studies

The program is an initiative of research leaders from the Brigham and Women’s Hospital, Boston, USA in collaboration with the PACE foundation.


Samuel Z Goldhaber, MD – Director of Vascular Medicine & Director, Thrombosis Research Group Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Faculty did not receive an honorarium for their lectures

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: